J Goodwin to Prostatic Neoplasms
This is a "connection" page, showing publications J Goodwin has written about Prostatic Neoplasms.
Connection Strength
2.475
-
Zanwar P, Lin YL, Kuo YF, Goodwin JS. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study. BMC Health Serv Res. 2016 Jan 15; 16:17.
Score: 0.250
-
Goodwin JS, Jaramillo E, Yang L, Kuo YF, Tan A. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study. PLoS One. 2014; 9(9):e107352.
Score: 0.227
-
Jaramillo E, Tan A, Yang L, Kuo YF, Goodwin JS. Variation among primary care physicians in prostate-specific antigen screening of older men. JAMA. 2013 Oct 16; 310(15):1622-4.
Score: 0.214
-
Goodwin JS, Tan A, Jaramillo E, Kuo YF. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials. J Natl Cancer Inst. 2013 May 15; 105(10):743-5.
Score: 0.205
-
Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013 Jan; 68(1):56-61.
Score: 0.193
-
Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009 Jan; 57(1):24-30.
Score: 0.152
-
Raji MA, Kuo YF, Freeman JL, Goodwin JS. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch Intern Med. 2008 Oct 13; 168(18):2033-40.
Score: 0.151
-
Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008 Jun; 112(11):2456-66.
Score: 0.147
-
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007 Dec 01; 25(34):5359-65.
Score: 0.142
-
Giordano SH, Lee A, Kuo YF, Freeman J, Goodwin JS. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer. 2006 Jul 15; 107(2):423-32.
Score: 0.129
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006 Jun 21; 98(12):839-45.
Score: 0.129
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006 Feb 27; 166(4):465-71.
Score: 0.126
-
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005 Apr 15; 103(8):1615-24.
Score: 0.119
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 Jan 13; 352(2):154-64.
Score: 0.116
-
Lackan NA, Ostir GV, Freeman JL, Mahnken JD, Goodwin JS. Decreasing variation in the use of hospice among older adults with breast, colorectal, lung, and prostate cancer. Med Care. 2004 Feb; 42(2):116-22.
Score: 0.109
-
Kuo YF, Goodwin JS, Shahinian VB. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. BMC Health Serv Res. 2008 Jul 14; 8:146.
Score: 0.037
-
Lackan NA, Ostir GV, Freeman JL, Kuo YF, Zhang DD, Goodwin JS. Hospice use by Hispanic and non-Hispanic white cancer decedents. Health Serv Res. 2004 Aug; 39(4 Pt 1):969-83.
Score: 0.028